The human T-cell leukemia virus type I (HTLV-I) is capable of chronically infecting various types of T cells and nonlymphoid cells. The effects of chronic infection on the specific functional activities and growth requirements of mature cytotoxic T lymphocytes (CTL) have remained poorly defined. We have, therefore, investigated the results of HTLV-I infection of both CD4+ and CD8+ human CTL clones. HTLV-I infection resulted in the establishment of functional CTL lines which propagated indefinitely in culture many months longer than the uninfected parental clone. The infected cells became independent of the need for antigen (target cell) stimulation as a requirement for proliferation and growth. Like their uninfected counterparts, however, these HTLV-I-infected clones remained strictly dependent on conditioned medium from mitogen-stimulated T lymphocytes for their growth. This growth factor requirement was not fulfilled by recombinant interleukin-2 alone. Furthermore, the infected lines remained functionally identical to their uninfected parental CTL clones in their ability to specifically recognize and lyse the appropriate target cells. Our findings indicate that the major effects of HTLV-I infection on mature CTL consist of (i) the capacity for proliferation in the absence of antigen stimulation and (ii) a prolonged or immortal survival in vitro, but they also indicate that the fine specificity and cytolytic capacity of these cells remain unaffected.
The human T-cell leukemia virus type I (HTLV-I) is a pathogenic retrovirus which is named for its ability to chronically infect T lymphocytes, but it can also grow in a number of other cell types (26, 29, 40) . HTLV-I was first isolated from adult patients with T-cell leukemias or lymphomas, and epidemiologic studies indicate that this virus is the etiologic agent of adult T-cell leukemia-lymphoma (3, 30, 31, 40) . Among the hallmarks of the adult T-cell leukemialymphoma syndrome is an impairment of immune function which results in a susceptibility to opportunistic infection. Because HTLV-I does not cause lysis of infected T lymphocytes, a number of investigators have studied the effects of a chronic HTLV-I infection on the immune phenotype and function of T cells. Infection of T cells of the CD4+ noncytotoxic subtype has in some cases resulted in a loss of specific antigen reactivity, with proliferation in response to any class II major histocompatibility complex (MHC) antigens (34, 35) or even in the absence of antigen (22, 23, 27, 37) . A decrease in the requirement for exogenous interleukin-2 (IL-2) for proliferation of infected lymphocytes has been frequently reported when the starting population of cells is heterogeneous, as in lymphocytes derived from bone marrow, cord blood, or peripheral blood (7, 20, 22, 27, 28) . Along with these virus-induced alterations in growth properties, trans-activation of certain cellular genes, including the class II MHC genes and the IL-2 receptor genes, has been reported (6, 15, 24, 27) .
Cytotoxic T lymphocytes (CTL) are one of the primary immune defenses of the host against viral infections and virus-induced tumors. The consequences of HTLV-I infection of cytotoxic T-cell lines or clones with well-defined antigen specificities, however, are not well understood. In a * Corresponding author.
total of four allospecific, CD4+ CTL clones, HTLV-I infection resulted in a progressive loss of cytotoxic function and specificity, accompanied by the progression of a transformed phenotype (27, 39) . A single CD8+ CTL, specific for HTLV-I, was also reported to have lost cytotoxic potential and continued to proliferate in culture without the need for stimulation with the appropriate antigen (23) .
To further investigate the impact of HTLV-I infection on human CTL, we have introduced the virus into a number of well-characterized human allospecific CTL clones expressing either the CD4+ or CD8+ phenotype. We report here that the viral infection of CTL clones rapidly resulted in the growth of cells independent of the need for antigen stimulation. These CTL clones proliferated indefinitely in culture but retained their cytotoxic capacity and specificity. heat-inactivated fetal calf serum (GIBCO Laboratories, Grand Island, N.Y.), penicillin (100 U/ml; GIBCO), streptomycin (100 U/ml; GIBCO), 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; Sigma Chemical Co., St. Louis, Mo.), and 25 ,uM 2-mercaptoethanol (Eastman Organic Chemicals, Rochester, N.Y.). Long-term CTL cultures and CTL clones were maintained in culture medium and 10% conditioned medium.
(ii) IL-2-containing human T-cell-conditioned medium. IL-2-containing medium was made as previously described (14 Nep- tune, N.J.) by stimulation every 1 to 2 weeks with irradiated stimulator cells. After 4 weeks in culture, the cells were again isolated by using a Ficoll-Hypaque gradient and cloned by using limiting dilution in 96-well round-bottom microtiter plates (Linbro, McLean, Va.) with 2 x 104 irradiated JY or M14B cells as a feeder layer. Culture medium containing 10% human conditioned medium was used for cloning; fresh medium was added every 3 days. Clones were obtained at a concentration of 1 cell per 10 wells. Both clones CTL-329 and CTL-342 were subcloned at less than 1 cell per well. The specificity of each clone was determined by using a panel of human leukocyte antigen (HLA)-typed target cells and monoclonal antibody (MAb) blocking as described previously (21) .
Blood lymphocyte preparation. Lymphocytes from peripheral blood or from cord blood were purified by banding in Ficoll-Hypaque. Lymphocytes were maintained in RPMI with 10% fetal calf serum and 10% T-cell-conditioned medium. Phytohemagglutinin was added to a concentration of 0.15% to stimulate proliferation prior to cocultivation with virus-producing cell lines.
Infection of lymphocytes with HTLV-I. The HTLV-I producer-cell line MJ (28, 29) was generously provided by M. Essex, Harvard School of Public Health, and was grown in RPMI with 10% fetal calf serum. The producer-cell line SPP was established from cord blood lymphocytes which had been transformed after cocultivation with MJ. The infected lymphocyte population was cloned by limiting dilution, and a clone which expressed HTLV-IMJ at high titers was selected and designated line SPP. Human T-cell-conditioned medium was added to 10% for 24 h before MJ or SPP was used for cocultivations to increase the production of virus. Immediately prior to cocultivation, the HTLV-I-producing cell line was irradiated to 10,000 rad with a gamma ray source. Cocultivations were carried out by using an equal number of irradiated producer cells and uninfected CTL or blood lymphocytes in the presence of 10% human T-cellconditioned medium and 8 jig of Polybrene (Sigma) per ml.
CTL were stimulated with the appropriate stimulator cells 2 days prior to the cocultivations to assure proliferation of the cells during the period of their exposure to the virus.
Lymphokines. Recombinant human interferon gamma and recombinant human T-cell growth factor (IL-2) were the generous gift of Biogen (Cambridge, Mass.).
Cytotoxicity assays. CTL assays were performed in triplicate in V-bottom microtiter wells (Linbro). Effector cells were added in threefold dilutions. Target cells, preincubated with 0.1 mCi of 51Cr (Na5"CrO4; New England Nuclear Corp., Boston, Mass.) for 2 h and washed three times, were added at 103 cells per well. Microtiter plates were centrifuged and incubated at 37°C for 4 h. After incubation, the plates were again centrifuged and the supernatants were assayed for 51Cr release. Specific cytotoxicity was calculated as percent cytotoxicity = (counts per minute of experimental release -counts per minute of spontaneous release)/ (total counts per minute -counts per minute of spontaneous release) x 100. When blocking MAb were used, they were added at the start of the assay. Inhibition of cytotoxicity was expressed as a percent reduction of the specific cytotoxicity. The standard deviation of the triplicate wells rarely exceeded 3 to 5% of the specific lysis. The uninfected CTL clones were stored frozen after cloning because of their limited life span in culture. Aliquots of the original clones CTL 329 and CTL 342 were thawed and stimulated once in culture prior to their inclusion in the cytotoxicity assays of their infected, immortal counterparts.
Proliferation assays. Proliferation of CTL was quantitated by incorporation of [3H]thymidine over a 24-h period. From 1 x 105 to 5 x 105 cells, some samples of which had been exposed to stimulator cells 48 h previously, were plated per well of a 24-well Linbro dish, in growth medium plus 10% human T-cell-conditioned medium. Cells were harvested and assayed for thymidine incorporation as described previously (9) . All assays were done in triplicate. In addition, parallel cultures were counted at 24-h intervals to assess the doubling time.
Cell surface immunofluorescence. have been previously described (5) . MAb recognizing HLA determinants were W6/32 (monomorphic HLA-A, -B, -C), LB3.1 (monomorphic HLA-DR), B7/21 (HLA-DP), and PA2.1 (HLA-A2, A28). The MAb TS1/22, recognizing the lymphocyte function-associated antigen 1, has been described elsewhere (32) . Commercially available MAb were also used: OKT3, OKT4, and OKT8 (Ortho, Raritan, N.J.) and Leu2, Leu3a, and anti-IL-2R (Becton Dickinson).
Analysis of HTLV-I transcripts and integrated proviruses. Total cellular RNA was extracted from cells, separated on the basis of size on formaldehyde-agarose gels, transferred to nitrocellulose, and hybridized to 32P-labeled DNA probes as previously described (38) . After being stripped, all blots were rehybridized with a P-actin-specific and/or a ,B-tubulin specific probe(s) to normalize for the total amounts of RNA added per lane. High-molecular-weight genomic DNA was isolated from cells essentially as described by Bell et al. (1) . This DNA was digested to completion with restriction endonucleases by using the conditions recommended by the manufacturer (New England BioLabs, Inc., Beverly, Mass.). Digested fragments were separated on the basis of size on agarose gels, transferred to nitrocellulose filters, and hybridized to 32P-labeled DNA probes by the method of Southern (33) . All washes of DNA and RNA blots were performed under conditions of high stringency (38) . Labeling of DNA probes was performed by using the random primerlabeling technique (10) . The P-actin, P-tubulin, and HLA probes were described previously (8, 38) . The HTLV-I probe consisted of an entire HTLV-I provirus (isolate MT-2) which had been cloned into pUC-18 via the SstI sites in the long terminal repeat (generously provided by J. Mullins, Harvard University).
RESULTS
Specificity of CTL clones. Human HLA class I-or class II-specific CTL lines were generated by repeated stimulation of peripheral blood lymphocytes from an HLA nonidentical donor with either the JY or the M14B cell line. These lines were cloned and subcloned by limiting dilution, and their phenotypes and functional characteristic specificities were determined by using MAb and HLA-typed target cell panels.
As expected, both CTL clones expressed CD3 (not shown). Clone CTL-329 was typical of the class I-specific CTL clones thus generated. All of the cells in this clone were simultaneously Leu2 (CD8) positive and Leu3 (CD4) negative, as determined by immunofluorescence analysis by two-color sorting (Fig. 1) . The lytic activity of this clone against its target (JY) was inhibited by 89% in the presence of CD8-reactive antibodies and by 82% in the presence of a pan-HLA-reactive antibody (W6/32). Antibodies against class II framework antigens or against CD4 had no effect on the cytotoxicity of CTL-329 (see below). Clone CTL-342, conversely, was typical of the class TI-specific CTL clones, and its phenotype was simultaneously positive for the CD4 antigen and negative for the CD8 antigen (Fig. 1) . The lytic activity of this clone was inhibited by 59% and 65% in the presence of antibodies directed against CD4 or HLA-DP, respectively, while antibodies recognizing CD8 or HLA class I framework antigens had no effect on its lytic activity.
The target specificity of CTL-329 is shown in Tables 1 and  2 . Target cell lines homozygous for HLA-A2 were recognized and lysed very efficiently by this clone. Cell lines heterozygous for A2 were lysed less efficiently, and lines negative for A2 expression were lysed poorly (at background levels). Furthermore, the lytic activity of this clone was (Tables 1 and 2 ) and was inhibited by MAb directed against HLA-DP. CTL-342 was therefore an HLA-DP3 responder expressing the CD4 phenotype.
Infected CTL clones contain HTLV-I genomes and express HTLV-T transcripts. These class I-or class II-specific CTL clones were then infected with HTLV-I by cocultivation with an irradiated, HTLV-ImJ-producing cell line called SPP. Several CTL clones which had been cocultivated were carried in parallel with cells from the same clone which had never been exposed to virus. Those CTL which had been exposed to the HTLV-I continued to grow and proliferate in culture. Two representative clones were selected and passaged for over 8 months, at which time it was elected to stop their continuous passage. CTL clones which had not been exposed to HTLV-I, however, did not proliferate beyond 6 weeks after mock infection, despite weekly stimulation with the original stimulator cell lines. The CD4 and CD8 cell surface phenotype of the CTL clones was unchanged after HTLV-I infection (Fig. 1) .
Total cellular RNA was extracted from the virus-producing cell line SPP, from uninfected bulk CTL, and from HTLV-I producer line SPP and in the cocultivated CTL clones (Fig. 2) . The 8.5-kilobase (kb) viral genome, the 4.0-kb env mRNA, and the 1.9-kb pX transcript were all detected. In contrast, no transcripts were detected in uninfected T-cell lines or in the parental bulk CTL line which had not been cocultivated with SPP (Fig. 2) . Analysis of the lines CTL-342-SPP and CTL-329-SPP, after 8 months in culture, demonstrated continued expression of HTLV-I transcripts in a pattern identical to that observed at 1 month in culture (not shown).
Genomic DNA was extracted from the virus-producing cell line used for cocultivation, from uninfected CTL bulk cultures, and from the CTL clones CTL-329-SPP and CTL-342-SPP, which had been cocultivated with the HTLV-I producer-cell line SPP. Digestion of genomic DNA containing an integrated HTLV-I provirus with EcoRI, which does not cut within the HTLV-IMJ genome (19, 23) , yields one or more fragments containing unique proviral integrations. Hybridization with a labeled DNA probe specific for HTLV-I demonstrated one or more viral integration sites in all of the infected or cocultivated cell lines but no HTLV-I integrations in the parental CTL bulk lines (Fig. 3) . There are two cleavage sites for BamHI in the HTLV-I genome, separated by approximately 1.0 kb. Digestion of the genomic DNA specimens with BamHI and hybridization with a labeled HTLV-I-specific probe identified this 1-kilobase-pair internal fragment in all the infected or cocultivated lines, along with multiple junction fragments (Fig. 3) .
The of the RNA derived from such a transformed cord blood lymphocyte population revealed HTLV-I-specific transcripts (Fig. 2) , demonstrating transmission of the virus from the CTL-SPP lines.
HTLV-I-infected clones upregulate expression of class I and class II MHC antigens and of the IL-2 receptor. mRNA and DNA analyses do not establish whether every cell in the population was infected and expressing HTLV-I. Immunoassay for the presence of the viral p24 antigen within the CTL by using a specific antiserum demonstrated low but specific levels of p24 immunoreactivity in 86 and 91% of the cells in the lines CTL-342-SPP and -329-SPP, respectively, when assayed at 8 months after infection (not shown). This same relative level of p24 expression has been noted in other HTLV-I-infected T-cell lines (12, 23) , including lines MJ and SPP. The levels of expression of cellular proteins which are known to be induced by HTLV-I infection (or by T-cell activation) were also examined. The levels of class II MHC antigen on the infected clones increased by a factor of 3.5 to 3.9 ( a Growth kinetics were assessed either 7 days after the last stimulation with the appropriate target cell (JY or M14B) (-), or 2 days after stimulation (+).
All the clones were cultured in medium containing 10%o human T-cell- c Estimated doubling time of clones, based on quantitation at 24-h intervals.
levels found after HTLV-I expression is due to enhancement of the expression of the normally expressed HLA antigens. HTLV-I-infected CTL clones do not require antigen stimulation for proliferation. Analysis of the growth kinetics of the infected or uninfected clones by using quantitation of cell number or uptake of [3H]thymidine demonstrated that the HTLV-I-infected clones CTL-342-SPP and CTL-329-SPP proliferated at about the same rate as the target cell-stimulated clones from which they were derived. Both the HTLV-I-infected and uninfected clones had a doubling time of approximately 50 h (Table 4) . Whereas the uninfected clones remained strictly dependent on exposure to stimulator (target) cells for proliferation, however, the HTLV-I-infected cells continued to proliferate at the same rate, whether or not they were stimulated with target cells at weekly intervals. Both the uninfected and infected CTL clones remained completely dependent on the presence of 10% human T-cell-conditioned medium for growth. Recombinant human IL-2, at concentrations up to 100 U/ml, was unable to substitute for this T-cell-conditioned medium requirement of all CTL lines. Gradual decreases in conditioned-medium concentration did not yield any conditionedmedium-independent CTL lines. Thus, proliferation of the HTLV-I-infected CTL had become antigen independent but not factor independent. Lymphocyte growth factors in addition to IL-2 continued to be required for the growth of these cells.
HTLV-I-infected CTL retain antigen specificity. Despite their lack of a requirement for antigen stimulation, the HTLV-I-infected CTL clones retained their ability to recognize and lyse cells bearing the appropriate MHC antigens. At both 1 month and 8 months after infection, line CTL-342-SPP remained specific for the class II antigen DP3 and lysed cells bearing DP3 at efficiencies similar to the original clone CTL-342 (Tables 1 and 2) . Similarly, line CTL-329-SPP retained its specificity for HLA-A2-bearing cells at 1 month and 8 months in culture. Furthermore, CTL-329-SPP preserved its fine HLA-A2 subtype specificity. After 8 months in culture, the infected line continued to recognize and lyse the A2 subtype-bearing target cells in the same hierarchical pattern as the parental clone (A2.1 > A2.2 > A2.3 >> A2.4) ( Table 5 ). The cytotoxicity of this HTLV-I-infected cell line was still blocked appropriately by antibodies directed against monomorphic HLA, HLA-A2, CD8, and CD3 after 8 months of continuous passage (Table 6 ). These results indicate that the HTLV-I-infected CTL continue to utilize the same antigen-independent cell-cell interaction molecules (25, 36, 39) . We find no major differences in the susceptibility of CTL clones to HTLV-I infection regardless of whether they express CD4 or CD8. The expression of CD3 was maintained on the infected CTL clones, consistent with their retention of antigen recognition and cytotoxic capacity.
Loss of CTL antigen-specific recognition and cytolytic function has been a universal finding in previous reports of HTLV-I-infected CTL lines and populations. In a total of 8 infected CTL lines described to date (5 allospecific [27, 35, 39] and 3 HTLV-I specific [23] ), all lost specific function or died within 2 months after infection. This loss of function was in some cases associated with a loss of CD3 expression on the cell surface. In addition, other investigators have reported the loss of antigen specificity with retention of the In the course of characterizing the expression of lymphoid cell surface antigens on the surface of CTL after infection with HTLV-I, the previously reported increases in IL-2 receptor antigen and class II MHC antigen expression were observed. In addition, a 5-to 10-fold increase in the levels of class I MHC (HLA) antigens were consistently observed after infection. High levels or alterations in HLA expression have been noted on HTLV-I-induced tumors or in populations of T lymphocytes infected with the virus (18) . Similarly, we report here that the HTLV-I-infected SPP cell line and HTLV-I-infected cord blood lymphocytes express substantially higher levels of HLA than do peripheral blood lymphocytes. Interpretation of such observations is difficult, however, because the phenotype of the original cell, prior to infection with the virus, could not be ascertained in such studies. By starting with well-characterized, clonal, untransformed T cells, we can demonstrate unequivocal consistent increases in class I MHC expression after HTLV-I infection. Furthermore, because the specific HLA type of these CTL clones is known, we can demonstrate that the increases in HLA expression are due to specific increases in the levels of the endogenous, normal HLA antigens expressed by the CTL, rather than to the expression of new or altered class I MHC-like molecules. Thus, this upregulation of HLA expression appears to be due to an effect of HTLV-I on the infected cell rather than to the cross-reactivity of the HTLV-I env antigen with panreactive anti-HLA antibodies (as proposed by Clarke et al. [4] ). Other lymphocyte cell surface antigens, including LFA-1, CD4, and CD8, are not upregulated in the infected CTL, indicating that there is a specificity to the upregulation of HLA antigens (and HLA-DR and IL-2R antigens) by the virus. We have previously reported that the murine leukemia retroviruses cause upregulation of class I MHC genes in the cells they infect by a trans-acting mechanism at the level of gene transcription (8, 11, 38) . The HTLV-I-infected CTL clones reported herein similarly express higher levels of class I MHC-specific mRNA transcripts than do their uninfected counterparts, suggesting a similar mechanism (D. V. Faller, unpublished data). Whether this HLA upregulation could be caused by the HTLV-I trans-acting tat gene is currently under investigation.
Our use of extensively characterized and stable cytotoxic T-lymphocyte clones, with well-defined functions and antigen specificities, has allowed us to elucidate the general and direct effects of HTLV-I infection on this effector arm of the cellular immune system. Loss of the need for antigen stimulation as a growth requirement occurred universally, as did the limitless potential for proliferation of the infected lymphocytes in culture. Both of these new characteristics could contribute to malignant behavior in vivo. However, a major change in growth factor requirements was not observed, and functional, cytotoxic antigen specificity was completely maintained over many months in culture. Thus, previous reports of growth factor autonomy, loss of CD3 expression and of function, and cell death in HTLV-I-infected T lymphocytes may represent secondary events occurring in culture, rather than direct results of the virus on the infected cells.
